Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ РКО, РОАГ, РАЭ, ЕАТ, РАФ

Климактерические симптомы могут нарушать ход жизни женщин на пике карьеры и семейной жизни. В настоящее время самым эффективным методом лечения этих проявлений является менопаузальная гормональная терапия (МГТ). Наличие сердечно-сосудистых и метаболических заболеваний само по себе не исключает возможность назначения МГТ с целью купирования климактерических симптомов и улучшения качества жизни. Однако нередко препятствием для использования этого вида гормональной терапии являются опасения врачей, боящихся принести пациенткам больше вреда, чем пользы. Осторожность особенно важна, когда речь идет о женщинах, страдающих сопутствующими заболеваниями. Более того, следует признать, что качественных исследований относительно безопасности МГТ при основных хронических неинфекционных заболеваниях и часто встречаемых коморбидных состояниях недостаточно. В представленном согласительном документе проведен анализ всех доступных в настоящее время данных, полученных в ходе клинических исследований различного дизайна, и создан свод критериев приемлемости назначения МГТ женщинам с сопутствующими сердечно-сосудистыми и метаболическими заболеваниями. Опираясь на представленный документ, врачи различных специальностей, консультирующие женщин в климактерии, получат доступный алгоритм, позволяющий избегать потенциально опасных ситуаций и обоснованно назначать МГТ в реальной практике.

1. Распоряжение Правительства Российской Федерации от 29 дек. 2022 г. № N 4356-р Об утверждении Национальной стратегии действий в интересах женщин на 2023-2030 годы. Доступно по: https://www.consultant.ru/document/cons_doc_LAW_436691 Ссылка активна на 16.08.2022.

2. Улумбекова Г.Э., Худова И.Ю. Оценка демографического, социального и экономического эффекта при приеме менопаузальной гормональной терапии // ОРГЗДРАВ: новости, мнения .Вестник ВШОУЗ. - 2020. - Т. 6, - №4. - С. 23-53. https://doi.org/10.24411/2411-8621-2020-14002

3. Lambrinoudaki I, Armeni E, Goulis D, et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022;(163):1-14. https://doi.org/10.1016/j.maturitas.2022.04.008

4. Адамян Л.В., Ашрафян Л.А., Андреева Е.Н., и др. Менопауза и климактерическое состояние у женщины. Клинические рекомендации. - М.: 2021. 86 c. Доступно по: https://cr.minzdrav.gov.ru/recomend/117_2. Ссылка активна на 20.10.2023

5. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10. Menopause. 2012;19(4):387-395. https://doi.org/10.1097/gme.0b013e31824d8f40

6. Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus. 2015;4(1):65. https://doi.org/10.1186/s40064-015-0808-y

7. Schnatz PF, Romegialli A, Abrantes J, et al. The North American Menopause Society: from abstract to publication. Menopause. 2008;15(5):996-1001. https://doi.org/10.1097/gme.0b013e318166f026

8. Paramsothy P, Harlow SD, Nan B, et al. Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women’s Health Across the Nation. Menopause. 2017;24(2):142-149. https://doi.org/10.1097/GME.0000000000000736

9. Сухих Г.Т., Сметник В.П., Андреева Е.Н., и др. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации. М.: 2015. С. 8-9. Доступно по: https://www.consultant.ru/document/cons_doc_LAW_320073. Ссылка активна на 20.10.2023

10. Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol. 2014;43(5):1542-1562. https://doi.org/10.1093/ije/dyu094

11. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924-932. https://doi.org/10.1097/GME.0000000000000196

12. Costanian C, Zangiabadi S, Bahous SA, et al. Reviewing the evidence on vasomotor symptoms: the role of traditional and non-traditional factors. Climacteric. 2020;23(3):213-223. https://doi.org/10.1080/13697137.2019.1711051

13. Prior JC. Progesterone for symptomatic perimenopause treatment-Progesterone politics, physiology and potential for perimenopause. Facts Views Vis Obstet Gynecol. 2011;(3):109-120.

14. Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44(3):497-515. https://doi.org/10.1016/j.ecl.2015.05.001

15. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза // Проблемы Эндокринологии. - 2017. - Т. 63. - №6. - С. 392-426. https://doi.org/10.14341/probl2017636392-426

16. Muka T, Oliver-Williams C, Colpani V, et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: A systematic review and meta-analysis. PLoS One. 2016;11(6):e0157417. https://doi.org/10.1371/journal.pone.0157417

17. Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. https://doi.org/10.3109/13697137.2015.1129166

18. Hirschberg AL, Bitzer J, Cano A, et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas. 2021;(148):55-61. https://doi.org/10.1016/j.maturitas.2021.04.005

19. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92(2):399-404. https://doi.org/10.1210/jc.2006-0513

20. Hu G. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia. 2003;46(5):608-617. https://doi.org/10.1007/s00125-003-1096-6

21. Vishram JK, Borglykke A, Andreasen AH, et al. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project [published correction appears in PLoS One. 2015;10(5):e0128848]. PLoS One. 2014;9(9):e107294. https://doi.org/10.1371/journal.pone.0107294

22. Драпкина О.М., Концевая А.В., Калинина А.М., и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022 // Кардиоваскулярная терапия и профилактика. 2022;21(4):3235. https://doi.org/10.15829/1728-8800-2022-3235

23. Cushman M. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573. https://doi.org/10.1001/jama.292.13.1573

24. Григорян О.Р., Андреева Е.Н. Ожирение и менопауза В кн: под ред. Г.А. Мельниченко, Н.К. Никифоровского. Ожирение у женщин - М.: Медицинское информационное агентство; 2017. С.233-268.

25. Caprio M, Antelmi A, Chetrite G, et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011;152(1):113-125. https://doi.org/10.1210/en.2010-0674

26. Rizzo MR, Leo S, De Franciscis P, et al. Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. Age (Dordr). 2014;36(1):265-274. https://doi.org/10.1007/s11357-013-9554-7

27. Дедов И.И., Шестакова М.В., Викулова О.К., и др. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021 // Сахарный диабет. - 2021. - Т. 24. - №3. - С. 204-221. https://doi.org/10.14341/DM12759

28. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. https://doi.org/10.1001/jama.2013.278040

29. Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538-554. https://doi.org/10.1111/j.1463-1326.2005.00545.x

30. Григорян О.Р. Менопаузальный синдром у женщин с cахарным диабетом // Сахарный диабет. - 2013. - Т. 16. - №3. - С. 103-108. https://doi.org/10.14341/2072-0351-824

31. Mendoza N, Ramírez I, de la Viuda E, et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. Maturitas. 2022;166(13):65-85. https://doi.org/10.1016/j.maturitas.2022.08.008

32. Kim J-E, Chang J-H, Jeong M-J, et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Sci Rep. 2020;10(1):20631. https://doi.org/10.1038/s41598-020-77534-9

33. Boardman HMP, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;2015(8). https://doi.org/10.1002/14651858.CD002229.pub4

34. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;2015(8):k4810. https://doi.org/10.1136/bmj.k4810

35. Goldštajn MŠ, Mikuš M, Ferrari FA, et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Arch Gynecol Obstet. 2022;307(6):1727-1745. https://doi.org/10.1007/s00404-022-06647-5

36. Kapoor E, Kling JM, Lobo AS, Faubion SS. Menopausal hormone therapy in women with medical conditions. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101578. https://doi.org/10.1016/j.beem.2021.101578

37. Morris G, Talaulikar V. Hormone replacement therapy in women with history of thrombosis or a thrombophilia. Post Reprod Heal. 2023;29(1):33-41. https://doi.org/10.1177/20533691221148036

38. Blondon M, Timmons AK, Baraff AJ, et al. Comparative venous thromboembolic safety of oral and transdermal postmenopausal hormone therapies among women Veterans. Menopause. 2021;28(10):1125-1129. https://doi.org/10.1097/GME.0000000000001823

39. Sobel TH, Shen W. Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scoping review. Menopause. 2022;29(4):483-490. https://doi.org/10.1097/GME.0000000000001938

40. Blondon M, Timmons AK, Baraff AJ, et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://doi.org/10.1097/GME.0000000000002028

41. Dinger J, Bardenheuer K, Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016;19(4):349-356. https://doi.org/10.1080/13697137.2016.1183624

42. Tepper NK, Whiteman MK, Marchbanks PA, et al. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678-700. https://doi.org/10.1016/j.contraception.2016.04.014

43. Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345(2):e4944-e4944. https://doi.org/10.1136/bmj.e4944

44. Nudy M, Chinchilli VM, Foy AJ. A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke. IJC Hear Vasc. 2019;(22):123-131. https://doi.org/10.1016/j.ijcha.2019.01.001

45. Cho L, Kaunitz AM, Faubion SS, et al. Rethinking menopausal hormone therapy: For whom, what, when, and how long? Circulation. 2023;147(7):597-610. https://doi.org/10.1161/CIRCULATIONAHA.122.061559

46. LaVasseur C, Neukam S, Kartika T, et al. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Res Pract Thromb Haemost. 2022;6(6):e12763. https://doi.org/10.1002/rth2.12763

47. Roach RE, Lijfering WM, van Hylckama Vlieg A, et al. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood. 2013;122(26):4264-4269. https://doi.org/10.1182/blood-2013-07-518159

48. Douketis JD, Julian JA, Crowther MA, et al. The effect of prothrombotic blood abnormalities on risk of deep vein thrombosis in users of hormone replacement therapy: a prospective case-control study. Clin Appl Thromb Hemost. 2011;17(6):E106-113. https://doi.org/10.1177/1076029610387587

49. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005;112(22):3495-3500. https://doi.org/10.1161/CIRCULATIONAHA.105.565556

50. Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M. Oral Contraceptives and HRT Risk of Thrombosis. Clin Appl Thromb. 2018;24(2):217-225. https://doi.org/10.1177/1076029616683802

51. Bezemer ID, van der Meer FJ, Eikenboom JC, et al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009;169(6):610-615. https://doi.org/10.1001/archinternmed.2008.589

52. Brighouse D. Hormone replacement therapy (HRT) and anaesthesia. Br J Anaesth. 2001;86(5):709-716. https://doi.org/10.1093/bja/86.5.709

53. Hulley S. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280(7):605. https://doi.org/10.1001/jama.280.7.605

54. Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women. JAMA. 2003;289(20):2673. https://doi.org/10.1001/jama.289.20.2673

55. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative. Circulation. 2006;113(20):2425-2434. https://doi.org/10.1161/CIRCULATIONAHA.105.594077

56. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. https://doi.org/10.1097/GME.0000000000001609

57. Nevine ID, te West NID, Day RO, et al. Estriol serum levels in new and chronic users of vaginal estriol cream: A prospective observational study. Neurourol Urodyn. 2020;39(4):1137-1144. https://doi.org/10.1002/nau.24331

58. Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361-370. https://doi.org/10.1097/GME.0000000000001463

59. Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2019;26(6):603-610. https://doi.org/10.1097/GME.0000000000001284

60. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11-20. https://doi.org/10.1097/GME.0000000000000956

61. Орлова Я.А., Плисюк А.Г., Долгушин Г.О., и др. Связь длительной менопаузальной гормональной терапии и показателей сосудистого и репликативного старения у женщин // Профилактическая медицина. - 2023. - Т. 26. - №7. - С. 96-102. https://doi.org/10.17116/profmed20232607196

62. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11(6):835-842. https://doi.org/10.1002/jbmr.5650110615

63. Nie G, Yang X, Wang Y, et al. The effects of menopause hormone therapy on lipid profile in postmenopausal women: A systematic review and meta-analysis. Front Pharmacol. 2022;13(1):11-20. https://doi.org/10.3389/fphar.2022.850815

64. Ежов М.В., Кухарчук В.В., Сергиенко И.В., и др. Нарушения липидного обмена. Клинические рекомендации 2023 // Российский кардиологический журнал. - 2023. - Т. 28. - №5. - С. 5471. https://doi.org/10.15829/1560-4071-2023-5471

65. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-2853. https://doi.org/10.1093/eurheartj/ehq386

66. van Dam-Nolen DHK, van Dijk AC, Crombag GAJC, et al. Lipoprotein(a) levels and atherosclerotic plaque characteristics in the carotid artery: The Plaque at RISK (PARISK) study. Atherosclerosis. 2021;(329):22-29. https://doi.org/10.1016/j.atherosclerosis.2021.06.004

67. Stevenson JC, Chines A, Pan K, et al. A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials. J Clin Endocrinol Metab. 2015;100(6):2329-2338. https://doi.org/10.1210/jc.2014-2649

68. Miller VT, LaRosa J, Barnabei V, et al. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1995;273(3):199-208. https://doi.org/10.1001/jama.1995.03520270033028

69. Binder EF, Birge SJ, Kohrt WM. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women. J Am Geriatr Soc. 1996;44(3):231236. https://doi.org/10.1111/j.1532-5415.1996.tb00907.x

70. Bunyavejchevin S, Limpaphayom KK. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial. J Med Assoc Thai. 2001;84(1):45-53.

71. Cayan F, Gen R, Akbay E, et al. The effect of hormone therapy and tibolone on glucose and lipid metabolism in healthy postmenopausal women. Turk Geriatr Derg. 2011;14(1)19-25. Available from: https://geriatri.dergisi.org/abstract.php?id=534

72. Cheng G, Liu J, Zhang Q, et al. Nylestriol replacement therapy in postmenopausal women. A three‐year prospective study. Int J Gynecol Obstet. 1995;48(1):137-137. https://doi.org/10.1016/0020-7292(95)90284-8

73. Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril. 1995;64(5):957-962. https://doi.org/10.1016/s0015-0282(16)57909-6

74. Conard J, Gompel A, Pelissier C, et al. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertil Steril. 1997;68(3):449-453. https://doi.org/10.1016/s0015-0282(97)00220-3

75. Davidson MH, Maki KC, Marx P, et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med. 2000;160(21):3315-3325. https://doi.org/10.1001/archinte.160.21.3315

76. Duvernoy CS, Rose PA, Kim HM, et al. Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot study. J Womens Health (Larchmt). 2007;16(7):963-970. https://doi.org/10.1089/jwh.2006.0321

77. Casanova G, dos Reis AM, Spritzer PM. Low-dose oral or non-oral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause. Climacteric. 2015;18(1):86-93. https://doi.org/10.3109/13697137.2014.940309

78. Haase CL, Tybjærg-Hansen A, Ali Qayyum A, et al. LCAT, HDL cholesterol and ischemic cardiovascular disease: A Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97(2):E248-E256. https://doi.org/10.1210/jc.2011-1846

79. Lv C, Zhang W, Tan X, et al. The effect of tibolone treatment on lipid profile in women: A systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacol Res. 2021;169(2):105612. https://doi.org/10.1016/j.phrs.2021.105612

80. Anagnostis P, Galanis P, Chatzistergiou V, et al. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. Maturitas. 2017;99(2):27-36. https://doi.org/10.1016/j.maturitas.2017.02.009

81. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 1992;99(10):821-828. https://doi.org/10.1111/j.1471-0528.1992.tb14414.x

82. Shufelt CL, Manson JE. Menopausal hormone therapy and cardiovascular disease: The role of formulation, dose, and route of delivery. J Clin Endocrinol Metab. 2021;106(5):1245-1254. https://doi.org/10.1210/clinem/dgab042

83. Anagnostis P, Bitzer J, Cano A, et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020;135(2):82-88. https://doi.org/10.1016/j.maturitas.2020.03.007

84. Wenger NK, Lloyd-Jones DM, Elkind MSV, et al. Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: A presidential advisory from the american heart association. Circulation. 2022;145(23):82-88. https://doi.org/10.1161/CIR.0000000000001071

85. Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385-2438. https://doi.org/10.1016/S0140-6736(21)00684-X

86. Reckelhoff JF. Gender differences in hypertension. Curr Opin Nephrol Hypertens. 2018;27(3):176-181. https://doi.org/10.1097/MNH.0000000000000404

87. Cho L, Davis M, Elgendy I, et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women. J Am Coll Cardiol. 2020;75(20):2602-2618. https://doi.org/10.1016/j.jacc.2020.03.060

88. Gerdts E, Sudano I, Brouwers S, et al. Sex differences in arterial hypertension. Eur Heart J. 2022;43(46):4777-4788. https://doi.org/10.1093/eurheartj/ehac470

89. Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-980. https://doi.org/10.1016/S0140-6736(21)01330-1

90. O’Keeffe LM, Simpkin AJ, Tilling K, et al. Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: A prospective cohort study. Atherosclerosis. 2018;278(10304):190-196. https://doi.org/10.1016/j.atherosclerosis.2018.09.030

91. Ji H, Kim A, Ebinger JE, et al. Sex differences in blood pressure trajectories over the life course. JAMA Cardiol. 2020;5(3):255. https://doi.org/10.1001/jamacardio.2019.5306

92. Maas AHEM, Rosano G, Cifkova R, et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J. 2021;42(10):967-984. https://doi.org/10.1093/eurheartj/ehaa1044

93. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation. 2020;142(25):967-984. https://doi.org/10.1161/CIR.0000000000000912

94. Biglia N, Cagnacci A, Gambacciani M, et al. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric. 2017;20(4):306-312. https://doi.org/10.1080/13697137.2017.1315089

95. Chapman N, Ching SM, Konradi AO, et al. Arterial hypertension in women: State of the art and knowledge gaps. Hypertension. 2023;80(6):1140-1149. https://doi.org/10.1161/HYPERTENSIONAHA.122.20448

96. Coutinho T. Arterial stiffness and its clinical implications in women. Can J Cardiol. 2014;30(7):756-764. https://doi.org/10.1016/j.cjca.2014.03.020

97. Picone DS, Kodithuwakku V, Mayer CC, et al. Sex differences in pressure and flow waveform physiology across the life course. J Hypertens. 2022;40(12):2373-2384. https://doi.org/10.1097/HJH.0000000000003283

98. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the american heart. Circulation. 2011;123(11):1243-1262. https://doi.org/10.1161/CIR.0b013e31820faaf8

99. Issa Z, Seely EW, Rahme M, et al. Effects of hormone therapy on blood pressure. Menopause. 2015;22(4):456-468. https://doi.org/10.1097/GME.0000000000000322

100. Mancia(Chairperson) G, Kreutz(Co-Chair) R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension endorsed by the International Society of Hypertension (ISH) and the European Renal Associati. J Hypertens. 2023;20(4):306-312. https://doi.org/10.1097/HJH.0000000000003480

101. Кобалава Ж.Д., Конради А.О., Недогода С.В., и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020 // Российский кардиологический журнал. - 2020. - Т. 25. - №3. - С. 3786. https://doi.org/10.15829/1560-4071-2020-3-3786

102. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166(7):772-780. https://doi.org/10.1001/archinte.166.7.772

103. Blondon M, Wiggins KL, Van Hylckama Vlieg A, et al. Smoking, postmenopausal hormone therapy and the risk of venous thrombosis: a population‐based, case-control study. Br J Haematol. 2013;163(3):418-420. https://doi.org/10.1111/bjh.12508

104. Li Y, Zhao D, Wang M, et al. Association of menopause with risk of carotid artery atherosclerosis. Maturitas. 2021;143(3):171-177. https://doi.org/10.1016/j.maturitas.2020.10.007

105. Schreinlechner M, Noflatscher M, Reinstadler SJ, et al. Early onset of menopause is associated with increased peripheral atherosclerotic plaque volume and progression. Atherosclerosis. 2020;297(3):25-31. https://doi.org/10.1016/j.atherosclerosis.2020.01.023

106. Westendorp IC, in’t Veld BA, Grobbee DE, et al. Hormone replacement therapy and peripheral arterial disease: the Rotterdam study. Arch Intern Med. 2000;160(16):2498-2502. https://doi.org/10.1001/archinte.160.16.2498

107. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). [Erratum in: JAMA. 2002;288(9):1064]. JAMA. 2002;288(1):49-57. https://doi.org/10.1001/jama.288.1.49

108. Rockman CB, Maldonado TS, Jacobowitz GR, et al. Hormone replacement therapy is associated with a decreased prevalence of peripheral arterial disease in postmenopausal women. Ann Vasc Surg. 2012;26(3):411-418. https://doi.org/10.1016/j.avsg.2011.10.012

109. Davies RS, Vohra RK, Bradbury AW, Adam DJ. The impact of hormone replacement therapy on the pathophysiology of peripheral arterial disease. Eur J Vasc Endovasc Surg. 2007;34(5):569-575. https://doi.org/10.1016/j.ejvs.2007.06.002

110. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196. https://doi.org/10.1016/S0140-6736(12)61729-2

111. Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372(14):1333-1341. https://doi.org/10.1056/NEJMoa1406656

112. Поляков Д.С., Фомин И.В., Беленков Ю.Н., и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА -ХСН // Кардиология. - 2021. - Т. 61. - №4. - С. 4-14. https://doi.org/10.18087/cardio.2021.4.n1628

113. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation. 2016;133(4):e38-e360. https://doi.org/10.1161/CIR.0000000000000350

114. Appiah D, Schreiner PJ, Demerath EW, et al. Association of age at menopause with incident heart failure: A prospective cohort study and meta-analysis. J Am Heart Assoc. 2016;5(8):e003769. https://doi.org/10.1161/JAHA.116.003769

115. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345(2):e6409-e6409. https://doi.org/10.1136/bmj.e6409

116. Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, et al. BEST Investigators. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. J Am Coll Cardiol. 2003;42(7):1238-1245. https://doi.org/10.1016/s0735-1097(03)00938-0

117. Liu L, Klein L, Eaton C, et al. Menopausal hormone therapy and risks of first hospitalized heart failure and its subtypes during the intervention and extended postintervention follow-up of the women’s health initiative randomized trials. J Card Fail. 2020;26(1):2-12. https://doi.org/10.1016/j.cardfail.2019.09.006

118. Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. https://doi.org/10.1093/eurheartj/ehw210

119. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005;112(12):1687-1691. https://doi.org/10.1161/CIRCULATIONAHA.105.553438

120. Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol. 2007;49(5):572-577. https://doi.org/10.1016/j.jacc.2006.10.047

121. Linde C, Bongiorni MG, Birgersdotter-Green U, et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace. 2018;20(10):1565-1565. https://doi.org/10.1093/europace/euy067

122. Thompson LE, Maddox TM, Lei L, et al. Sex differences in the use of oral anticoagulants for atrial fibrillation: A report from the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. J Am Heart Assoc. 2017;6(7):e005801. https://doi.org/10.1161/JAHA.117.005801

123. Lee J, Kim Y, Park H, et al. Clinical impact of hormone replacement therapy on atrial fibrillation in postmenopausal women: A nationwide cohort study. J Clin Med. 2021;10(23):5497. https://doi.org/10.3390/jcm10235497

124. Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: Results from the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017;136(17):1588-1597. https://doi.org/10.1161/CIRCULATIONAHA.117.028981

125. Perez MV, Wang PJ, Larson JC, et al. Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women’s Health Initiative randomized controlled trials. Circ Arrhythm Electrophysiol. 2012;5(6):1108-1116. https://doi.org/10.1161/CIRCEP.112.972224

126. Tsai W-C, Haung Y-B, Kuo H-F, et al. Hormone replacement therapy and risk of atrial fibrillation in Taiwanese menopause women: A nationwide cohort study. Sci Rep. 2016;6(1):24132. https://doi.org/10.1038/srep24132

127. Wong JA, Rexrode KM, Sandhu RK, et al. Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. Heart. 2017;103(24):1954-1961. https://doi.org/10.1136/heartjnl-2016-311002.

128. Fleury MA, Clavel MA. Sex and race differences in the pathophysiology, diagnosis, treatment, and outcomes of valvular heart diseases. Can J Cardiol. 2021;37(7):980-991. https://doi.org/10.1016/j.cjca.2021.02.003